Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

IsraelRecruitingPHASE3

Conditions

Primary Immunoglobulin A Nephropathy (IgAN)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Childrens Hospital Colorado, Aurora, Colorado, United States
Contact: Study coordinator (Claire Giachino) · claire.giachino@childrenscolorado.org · +1 720 777 1234
Contact: Principal Investigator (Bradley Dixon)
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Catherine Justice) · justicec@chop.edu · +1 267 426 9338
Contact: Principal Investigator (Rebecca Scobell)
Prim Childrens Hosp Inv Pharm, Salt Lake City, Utah, United States
Contact: Study coordinator (Gabriella Gourdin) · gabriella.gourdin@hsc.utah.edu
Contact: Principal Investigator (Raoul Nelson)
Novartis Investigative Site, Brisbane, Queensland, Australia
Novartis Investigative Site, Nedlands, Western Australia, Australia
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Hong Kong, Hong Kong
Novartis Investigative Site, Beersheba, Israel
Novartis Investigative Site, Haifa, Israel
Novartis Investigative Site, Jerusalem, Israel
Novartis Investigative Site, Petah Tikva, Israel
Novartis Investigative Site, Toyoake, Aichi-ken, Japan
Novartis Investigative Site, Kurume, Fukuoka, Japan
Novartis Investigative Site, Ohtsu, Shiga, Japan
Novartis Investigative Site, Fuchū, Tokyo, Japan
Novartis Investigative Site, Riyadh, Saudi Arabia

Study leads

Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

View source on ClinicalTrials.gov Contact study team (email)